Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
- Both companies will collaborate to advance a small molecule condensate modulator targeting TDP-43, with the potential to address the underlying pathology of <97% of ALS patients - Mitsubishi...
-
Orally administered small molecule condensate modulators (c-mods) are a novel class of therapeutic agents designed to target condensates to modify diseaseDPTX3186 is Dewpoint’s first development...
-
Bayer obtains global license to develop and commercialize disease-modifying treatment specifically for dilated cardiomyopathy (DCM) patients characterized by specific mutationsPost-licensing,...
-
Grant to support the in vivo development of first-in-class condensate-modifying drugs (c-mods) targeting the TDP-43 condensatopathy in ALS BOSTON, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Dewpoint...
-
The in-kind Target ALS Foundational grant will support the development of first-in-class condensate-modifying drugs (c-mods) targeting the TDP-43 condensatopathy in ALS animal model BOSTON, Jan. ...
-
Patent applications reinforce Dewpoint’s leadership in the discovery of condensate-modifying drugs (c-mods) to treat diseases of high unmet needNew first-in-class composition of matter targeting...
-
PARTNERSHIP TO ACCELERATE DEWPOINT’S LEADING ONCOLOGY PIPELINE PROGRAMS TO INVESTIGATIONAL NEW DRUG APPLICATIONS COLLABORATION LEVERAGES EVOTEC’S FULLY INTEGRATED, CLINICAL-ENABLING INDIGO CAPABILITY...